Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. [electronic resource]
Producer: 20020628Description: 378-84 p. digitalISSN:- 1466-4860
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents -- administration & dosage
- B-Lymphocytes -- drug effects
- Blood Cell Count
- Complement Activation -- drug effects
- Complement C3a -- drug effects
- Humans
- Kinetics
- L-Lactate Dehydrogenase -- blood
- Lymphoma, B-Cell -- drug therapy
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Middle Aged
- Rituximab
- Tumor Necrosis Factor-alpha -- drug effects
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.